ACM Global appoints Asia Pacific general manager

He will initially build ACM Global team in India

ACM Global Central Laboratory has announced the newest member of its Clinical Trials team, Nandan Rao as general manager, Asia Pacific. He will be located in Mumbai, India and initially will have oversight of trials conducted with ACM Global’s partner lab in the region.

Rao will also be building the ACM Global infrastructure and team throughout Asia Pacific.

Rao was formerly general manager of SRL, the largest clinical reference laboratory network in India and Southeast Asia, where he built the firm’s clinical trials operations.

‘Since establishing its presence in India in 2006, ACM has become a global leader in the central lab arena,’ said Elena Logan, VP of Clinical Trials at ACM Global Central Lab.

‘Nandan’s expertise in building a central lab group in this region will be of significant value to our organisation as we continue to expand ACM Global wholly owned locations.’

You may also like

Regulatory

ACM Global relocates European hq to expanded lab facilities

Moves into a new, state-of-the-art facility in York, UK
Regulatory

ACM Global Central Laboratory establishes Mumbai subsidiary

Operational facility is dedicated to managing clinical trials testing in India and study support in Asia Pacific
Finance
Viral vector CDMO VintaBio’s Philadelphia facility and IP up for sale

Viral vector CDMO VintaBio’s Philadelphia facility and IP up for sale

VintaBio’s assignee is seeking bids for its cGMP facility, equipment and proprietary AAV technology as gene therapy contract manufacturers face overcapacity
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Manufacturing
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India

Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India

The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
Finance
Merck KGaA divests US CDMO business to Lonza

Merck KGaA divests US CDMO business to Lonza

Merck KGaA will sell its US CDMO business to Lonza in a deal worth hundreds of millions of Swiss francs, expanding Lonza's US manufacturing footprint and marking a strategic shift for Merck
You need to be a subscriber to read this article.
Click here to find out more.
Packaging
Embracing healthcare innovation with 2D codes

Embracing healthcare innovation with 2D codes

Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
Subscribe now